S. Jafri

Risk factors for breast cancer in patients treated at NORI Hospital, Islamabad.

Z. Hasan, M. Khurram, M. Faheem, 2007, JPMA. The Journal of the Pakistan Medical Association.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer

R. Pazdur, L. Amiri-Kordestani, M. Kondratovich, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.